BRAF targets in melanoma. Biological mechanisms, resistance, and drug discovery. Cancer drug discovery and development. Volume 82. Ed. Ryan J. Sullivan. Springer (2015)
Patients initially assigned to dabrafenib monotherapy were eligible for crossover to combination therapy. In this BRAF inhibitor resistant population, the combination was much less effective (median PFS 3.6 months, objective response rate 9%) compared to BRAF inhibitor naпve patients . A long duration of PFS on dabrafenib monotherapy appeared to predict a longer benefit from crossover although this was not universal. Patients who rapidly progressed on dabrafenib generally received minimal or no benefit from the combination. In our opinion, BRAF inhibitor resistant patients could be considered for crossover if they derive a long term benefit from monotherapy (> 12 months).
[contact-form-7 id=»5168″ title=»Контактная форма 1″]